Redeye provides a comment on Dignitana’s Q1 2025 report.
Redeye’s forecasts and valuation remain unchanged following today’s announced outcome of the TO3 war...
Redeye comments on Cinclus Pharma’s announcement earlier today of a EUR220m licensing agreement with...
The major decrease in sales compared to Q1 2024 was expected.
Redeye provides a brief comment on today’s news that Freemelt has signed an agreement with a leading...
Redeye comments on Jumpgate’s Q1 2025 report, which contained no major surprises and delivered a top...
Redeye shares its initial take on Genovis following the Q1 report, which delivered sales 13% above o...
Redeye shares its initial impressions of NextCell’s recently announced collaboration with Fujifilm I...
Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi...
Redeye comments on Better Collective’s Q1-results which were somewhat better than expected as revenu...
Q1 miss mainly driven by FK and SDR Cutting '25e EBITDA/EBIT by 9/15%, small changes to '26e-'27e FV...
Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m FY'25 guidance maintained, as expected Consens...
Redeye comments on today's news that Curasight's share issue was subscribed to 47%, raising DKK47m b...
Redeye comments on Flexion Mobile's Q1 2025 report, which was pretty much in line with expectations.
Redey comments on Oncopeptides’ first quarter report 2025.
Redeye is satisfied with TO12's preliminary subscription rate of 71%.
Redeye provides a research update following the Q1 report published by Cinclus earlier today.
Redeye returns with a more in-depth take on the Q1 earnings.
Redeye provides a brief comment on Kancera’s update regarding the collaboration with Recardio and th...
Redeye retains its positive view of Lagercrantz after a Q4 report that aligned with our projections.
